<DOC>
	<DOCNO>NCT00432614</DOCNO>
	<brief_summary>The primary objective study compare , 8 week , efficacy SR58611A vs. placebo patient Major Depressive Disorder concomitant treatment escitalopram . The secondary objective study document clinical safety tolerability SR58611A association escitalopram .</brief_summary>
	<brief_title>Efficacy Safety SR58611A co-Administered With Escitalopram Adults With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inpatients outpatient Major Depressive Disorder characterize recurrent Major Depressive Episode Montgomery Asberg Depression Rating Scale ( MADRS ) total score = &gt; 30 Patient immediate risk suicidal behavior Patient psychotic feature , catatonic feature , seasonal pattern postpartum onset Patients current depressive episode secondary general medical disorder Patients lifetime history presence bipolar disorder , psychotic disorder , panic disorder antisocial personality disorder Patients severe unstable concomitant medical condition Pregnant , breastfeeding , likely become pregnant study Treated escitalopram within 6 month study , adverse reaction escitalopram The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Mental Disorder</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Depressive Disorder</keyword>
</DOC>